Impact of flavan-3-ols on blood pressure and endothelial function in diverse populations: a systematic review and meta-analysis of randomised controlled trials.
Vasiliki Lagou, Arno Greyling, Mario Ferruzzi, Simon S Skene, Joy Dubost, Ayse Demirkan, Inga Prokopenko, Julie Shlisky, Ana Rodriguez-Mateos, Christian Heiss
{"title":"Impact of flavan-3-ols on blood pressure and endothelial function in diverse populations: a systematic review and meta-analysis of randomised controlled trials.","authors":"Vasiliki Lagou, Arno Greyling, Mario Ferruzzi, Simon S Skene, Joy Dubost, Ayse Demirkan, Inga Prokopenko, Julie Shlisky, Ana Rodriguez-Mateos, Christian Heiss","doi":"10.1093/eurjpc/zwaf173","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Flavan-3-ols, found in cocoa, tea, and certain fruits, show promise in improving blood pressure (BP) and vascular function, but are currently not used for cardiovascular prevention. This meta-analysis evaluated the effects of flavan-3-ol-rich interventions on BP and endothelial function.</p><p><strong>Methods: </strong>PubMed was searched for randomized controlled trials (RCTs) published 1946-03/2024 on BP and flow-mediated dilation (FMD) after flavan-3-ol-rich food, beverage, or supplement intake. Random-effects meta-analysis of 109 publications including 145 RCTs and 5,205 participants was performed. (PROSPERO:CRD42023454691).</p><p><strong>Results: </strong>Flavan-3-ol interventions included epicatechin, epigallocatechin-gallate, cocoa products, tea, grape extract, and apples delivering 586 mg (95%CI 510,662) total flavan-3-ols. Interventions decreased office (-2.8 [95%CI -3.9, -1.7]/-2.0 [-2.6, -1.3] mmHg) and 24h-ambulatory BP (-3.7 [-5.8, -1.6]/-2.6 [-4.5, -0.8] mmHg) after chronic repetitive consumption. Effects were larger with elevated and hypertensive baseline BP or categorical hypertension (office: -5.9 [-10.0, -1.8]/-2.7 [-4.4, -1.0] mmHg, 24h-ABP: -6.8 [-16.3,2.8]/-5.1 [-12.5,2.2] mmHg). Meta-regression analysis confirmed that the magnitude of BP lowering was inversely related to baseline BP, but not to proportion of participants with CVD, diabetes mellitus, and study duration across all studies, and was dose-dependently related to epicatechin dose only in cocoa studies. FMD increased after acute (+2.0% [1.6,2.3]) and repetitive (+1.7% [1.3,2.2]) consumption independent of BP. Reported adverse events were minor and low (0.4%). The considerable heterogeneity of effect sizes (I2>50%) between studies was not explained by the investigated factors limiting the strength of evidence to 'moderate'.</p><p><strong>Conclusions: </strong>Flavan-3-ol-rich foods considerably reduce elevated BP and improve endothelial function independent of blood pressure supporting their use for cardiovascular prevention.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwaf173","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: Flavan-3-ols, found in cocoa, tea, and certain fruits, show promise in improving blood pressure (BP) and vascular function, but are currently not used for cardiovascular prevention. This meta-analysis evaluated the effects of flavan-3-ol-rich interventions on BP and endothelial function.
Methods: PubMed was searched for randomized controlled trials (RCTs) published 1946-03/2024 on BP and flow-mediated dilation (FMD) after flavan-3-ol-rich food, beverage, or supplement intake. Random-effects meta-analysis of 109 publications including 145 RCTs and 5,205 participants was performed. (PROSPERO:CRD42023454691).
Results: Flavan-3-ol interventions included epicatechin, epigallocatechin-gallate, cocoa products, tea, grape extract, and apples delivering 586 mg (95%CI 510,662) total flavan-3-ols. Interventions decreased office (-2.8 [95%CI -3.9, -1.7]/-2.0 [-2.6, -1.3] mmHg) and 24h-ambulatory BP (-3.7 [-5.8, -1.6]/-2.6 [-4.5, -0.8] mmHg) after chronic repetitive consumption. Effects were larger with elevated and hypertensive baseline BP or categorical hypertension (office: -5.9 [-10.0, -1.8]/-2.7 [-4.4, -1.0] mmHg, 24h-ABP: -6.8 [-16.3,2.8]/-5.1 [-12.5,2.2] mmHg). Meta-regression analysis confirmed that the magnitude of BP lowering was inversely related to baseline BP, but not to proportion of participants with CVD, diabetes mellitus, and study duration across all studies, and was dose-dependently related to epicatechin dose only in cocoa studies. FMD increased after acute (+2.0% [1.6,2.3]) and repetitive (+1.7% [1.3,2.2]) consumption independent of BP. Reported adverse events were minor and low (0.4%). The considerable heterogeneity of effect sizes (I2>50%) between studies was not explained by the investigated factors limiting the strength of evidence to 'moderate'.
Conclusions: Flavan-3-ol-rich foods considerably reduce elevated BP and improve endothelial function independent of blood pressure supporting their use for cardiovascular prevention.
期刊介绍:
European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.